ADC solutions at Sterling
Unlocking the full potential of complex antibody drug conjugates (ADCs) requires a partner with the experience and capacity to solve even the most rigorous scientific challenges. Drawing upon years of experience working with ADCs from their earliest inception, our dedicated bioconjugation team is committed to supporting your project from discovery to preclinical scale up; pro-actively overcoming ADC challenges and helping you to develop the next generation of ADC candidates.
Our bioconjugation team has a track record of more than 10 years dedicated to supporting ADC discovery and development, and we are committed to ushering in a new era of cancer treatment, as well as the entry of this breakthrough technology into other therapeutic areas.
Our experience working with a wide range of targeting molecules, linkers, conjugation chemistries, and toxins enables us to take on the most complex ADC projects and proactively overcome challenges associated with ADC development. We work closely with customers to develop tailored processes to accomplish your ADC objectives. Our facilities support containment and are designed with safety in mind — we are committed to ensuring your process’ quality, safety, and scalability.
Our multidisciplinary bioconjugation team is wholly focused on ADC discovery and development, led by a range of ADC experts with backgrounds in chemistry, biochemistry, and biology.
10-year track record:
Founded as a specialist in ADC discovery and development, our bioconjugation division has successfully worked with ADCs for more than 10 years.
Our Deeside, Wales, UK facility is fully equipped to support bioconjugate research and development.
Our experience working with different antibodies, linkers, and toxins enables us to develop a customised bioconjugation approach that supports your unique requirements.
What are ADCs and why are they so groundbreaking?
Unlike traditional therapeutics, ADCs deliver cancer treatment that is both highly targeted and highly potent. Composed of a monoclonal antibody (mAb), a linker, and a toxin, ADCs directly attack cancerous cells while avoiding harm to healthy ones. These ‘magic bullets’ have shown great promise in treating cancer where other therapies have failed, and are now being explored as a treatment option for infectious diseases, inflammatory diseases, and autoimmune diseases.
A specialised team, a single objective
Our bioconjugation team has more than 35 years of collective expertise working specifically with ADCs. With backgrounds in chemistry, biochemistry, and biology, our scientists share one common goal, to transform the treatment of cancer and other infectious or chronic conditions. We work closely with you throughout your project to develop efficient processes, maximise effectiveness, and ensure scalable and repeatable results. ... Read more
Our dedicated ADC centre of excellence at Deeside (formerly ADC Biotechnology) has experience working with an extensive range of antibodies, as well as other targeting molecules, such as antibody fragments.
Our team has used a range of different conjugation technologies and has worked with many different classes of payload, from highly potent PBD’s to non-potent molecules; designing the right linker to compliment both payload and target. Read less